Clinical and Laboratory Aspects of Thyroglobulin and Thyroglobulin Antibody in Differentiated Thyroid Carcinoma
DOI:
https://doi.org/10.31584/jhsmr.2022862Keywords:
antithyroglobulin, differentiated thyroid cancer, thyroglobulinAbstract
Thyroglobulin (Tg) is a precursor for thyroid hormone, specifically synthesized by thyroid follicular cells upon stimulation by the thyroid stimulating hormone (TSH). Damage to the thyroid cells caused by benign or malignant thyroid diseases cause the release of Tg into circulation. Differentiated thyroid cancer (DTC) is the most common endocrine malignancy, which has an excellent prognosis if detected and treated early. This review describes the clinical and laboratory aspects of Tg and AntiTg measurement in the management of DTC. The serum Tg measurement has been used in the pre- and post-operative management of DTC. The clinical significance of Tg and the role its low level can play in the diagnosis and monitoring of DTC as well as in the prediction of its recurrence must be understood. DTC may lead to the production of a different Tg with novel immunogenic cancer epitopes that can induce TgAb synthesis. The preoperative TgAb level has shown a high predictive value for DTC, while postoperative serum TgAb can be used for the detection of disease persistence and recurrence. Despite the importance of TgAb level in DTC management, the presence of TgAb interferes with the analysis of Tg measurement, thus limiting its clinical utility. There is no established value regarding at which level TgAb interferes with Tg measurement. Available methods in measuring Tg and TgAb should emphasize the lower and upper limits of their detection, especially for postoperative monitoring and early disease recurrence detection. The accurate measurement of serum Tg and TgAb is pertinent to the follow-up of DTC patients, and any suspicious results must be interpreted in accordance with clinical findings in view of a present possible assay interference.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer Clin 2018;68:394-424.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
Mitchell A, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol 2016;130:S150-60.
Evans C, Tennant S, Perros P. Thyroglobulin in differentiated thyroid cancer. Clinica Chimica Acta 2015;444:310-7.
Bilek R, Dvorakova M, Grimmichova T, Jiskra J. Iodine, thyro globulin and thyroid gland. Physiol Res 2020;69(Suppl 2): S225-36.
Xavier ACW, Maciel R, Vieira JGH, Dias-da-Silva MR, Martins JR. Insights into the posttranslational structural heterogeneity of thyroglobulin and its role in the development, diagnosis, and management of benign and malignant thyroid diseases. Arch Endocrinol Metab 2016;60:66-75.
Citterio CE, Targovnik HM, Arvan P. The role of thyroglobulin in thyroid hormonogenesis. Nat Rev Endocrinol 2019;15:323- 38.
Clark P, Franklyn J. Can we interpret serum thyroglobulin results? Ann Clin Biochem 2012;49:313-22.
Doggui R, editor. Immunoanalytical profile of thyroglobulin anti bodies. Ann Bio Clin (Paris) 2018;76:695-704.
Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, et al. Disappearance of humoral thyroid auto immunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-51.
D’Aurizio F, Metus P, Ferrari A, Caruso B, Castello R, Villalta D, et al. Definition of the upper reference limit for thyro globulin antibodies according to the National Academy of Clinical Biochemistry guidelines: comparison of eleven different automated methods. Auto Immun Highlights 2017;8: 1-10.
Hulikal N, Azhagamuthu R, Banoth M, Chowhan AK, Yutla M, Sachan A. Can preoperative serum thyroglobulin levels predict the risk of malignancy? Results from prospective analysis of biochemical predictors of malignancy in thyroid nodules. Acta Otorhinolaryngol Ital 2020;40:33.
Kars A, Aktan B, Kilic K, Sakat MS, Gözeler MS, Yörük Ö, et al. Preoperative serum thyroglobulin level as a useful predictive marker to differentiate thyroid cancer. ORL 2018;80: 290-5.
Wang Z, Kang J, Guo B, Deng X, Bo W, Fan Y. Preoperative serum thyroglobulin in prediction of follicular thyroid tumors. Chin J Endocr Surg 2017;11:391-4.
Kim HJ. Updated guidelines on the preoperative staging of thyroid cancer. Ultrasonography 2017;36:292.
Kim H, Kim YN, Kim HI, Park SY, Choe JH, Kim JH, et al. Preoperative serum thyroglobulin predicts initial distant meta stasis in patients with differentiated thyroid cancer. Sci Rep 2017;7:1-7.
Kim H, Park SY, Choe JH, Kim JS, Hahn SY, Kim SW, et al. Preoperative serum thyroglobulin and its correlation with the burden and extent of differentiated thyroid cancer. Cancers 2020;12:625.
Rageh TM, Abdou AG, Elkhouly EA, Abou El-Ela DH, Zidan MA. Preoperative significance of thyroglobulin, thyroid stimulat ing hormone and thyroglobulin antibody in differentiated papillary thyroid carcinoma. Int Surg J 2019;6:4229-37.
Patell R, Mikhael A, Tabet M, Bena J, Berber E, Nasr C. Assessing the utility of preoperative serum thyroglobulin in differentiated thyroid cancer: a retrospective cohort study. Endocrine 2018;61:506-10.
Atilgan HI, Yalcin H. Estimation of residual tissue with thyroid scintigraphy and thyroglobulin level in the pre-ablative period differentiated thyroid carcinoma. Ulutas Med J 2020;6:169-75.
McDow AD, Shumway CM, Pitt SC, Schneider DF, Sippel RS, Long KL. Utility of early postoperative unstimulated thyro-globulin in influencing decision making in patients with papillary thyroid carcinoma. Ann Surg Oncol 2019;26:4002-7.
Prpić M, Franceschi M, Romić M, Jukić T, Kusić Z. Thyro globulin as a tumor marker in differentiated thyroid cancer–clinical considerations. Acta Clinica Croatica 2018;57:518-26.
Jammah AA, Masood A, Akkielah LA, Alhaddad S, Alhaddad MA, Alharbi M, et al. Utility of stimulated thyroglobulin in reclassi fying low risk thyroid cancer patients’ following thyroidectomy and radioactive iodine ablation: a 7-year prospective trial. Front Endocrinol 2020;11.
Jayasekara J, Jonker P, Lin JF, Engelsman AF, Wong MS, Kruijff S, et al. Early postoperative stimulated serum thyro globulin quantifies risk of recurrence in papillary thyroid cancer. Surgery 2020;167:40-5.
Campennì A, Giovanella L, Pignata SA, Vento A, Alibrandi A, Sturiale L, et al. Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. Oncotarget 2018;9:17491.
Alhefdhi A, Altayyar T, Alqahtani SM, Alshehri M, Elnaas S, Alsobhi S. Can preoperative serum thyroglobulin and anti thyroglobulin levels predict malignant potential of a thyroid nodule with atypia or follicular lesion of undetermined signi ficance?. Otorhinolaryngol Head Neck Surg 2020:5:1-4
Drake T. Serum antithyroglobulin antibodies predict differentiated thyroid cancer persistence/recurrence and Mortality. Clinical Thyroidology 2020;32:344-6.
Matrone A, Latrofa F, Torregrossa L, Piaggi P, Gambale C, Faranda A, et al. Changing trend of thyroglobulin antibodies in patients with differentiated thyroid cancer treated with total thyroidectomy without 131I ablation. Thyroid 2018;28:871-9.
Ernaga-Lorea A, Hernandez-Morhain M, Anda-Apinaniz E, Pineda-Arribas J, Migueliz-Bermejo I, Eguilaz-Esparza N, et al. Prognostic value of change in anti-thyroglobulin anti bodies after thyroidectomy in patients with papillary thyroid carcinoma. Clin Transl Oncol 2018;20:740-4.
Lee ZJO, Eslick GD, Edirimanne S. Investigating antithyro globulin antibody as a prognostic marker for differentiated thyroid cancer: a meta-analysis and systematic review. Thyroid 2020;30:1601-12.
Reverter JL, Rosas-Allende I, Puig-Jove C, Zafon C, Megia A, Castells I, et al. Prognostic significance of thyroglobulin anti bodies in differentiated thyroid cancer. J Thyroid Res 2020;2020.
Hocevar M, Auersperg M, Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol 1997;23:208-10.
Giovanella L, Ceriani L, Maffioli M. Postsurgery serum thyro globulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head Neck 2010;32:568-71.
Patel A, Shostrom V, Treude K, Lydiatt W, Smith R, Goldner W. Serum thyroglobulin: preoperative levels and factors affecting postoperative optimal timing following total thyroi dectomy. Int J Endocrinol 2019;2019.
Spencer CA, LoPresti JS. Technology Insight: measuring thyro globulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008;4:223-33.
Algeciras-Schimnich A. Thyroglobulin measurement in the management of patients with differentiated thyroid cancer. Crit Rev Clin Lab Sci 2018;55:205-18.
Netzel BC, Grebe SK, Carranza Leon BG, Castro MR, Clark PM, Hoofnagle AN, et al. Thyroglobulin (Tg) testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes. J Clin Endocrinol Metab 2015;100:E1074-E83.
Azmat U, Porter K, Senter L, Ringel MD, Nabhan F. Thyro globulin liquid chromatography–tandem mass spectrometry has a low sensitivity for detecting structural disease in patients with antithyroglobulin antibodies. Thyroid 2017;27:74-80.
Shuford CM, Johnson JS, Thompson JW, Holland PL, Hoofnagle AN, Grant RP. More sensitivity is always better: measuring sub-clinical levels of serum thyroglobulin on a µLC–MS/MS system. Clinical Mass Spectrometry 2020;15:29-35.
Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-126.
Giovanella L, Feldt-Rasmussen U, Verburg FA, Grebe SK, Plebani M, Clark PM. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. Clin Chem Lab Med 2015;53:1301-14.
Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, et al, editors. Human thyroglobulin reference material (CRM 457). 1st part: assessment of homogeneity, stability and immunoreactivity. Ann Bio Clin (Paris) 1996;54: 337-42.
Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, et al, editors. Human thyroglobulin reference material (CRM 457). 2nd part: physicochemical characterization and certification. Ann Bio Clin (Paris) 1996;54:343-8.
Filetti S, Durante C, Hartl D, Leboulleux S, Locati L, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30: 1856-83.
Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. 2019 European Thyroid Association guide lines for the treatment and follow-up of advanced radioiodine refractory thyroid cancer. Euro Thyroid J 2019;8:227-45.
Hillebrand J, Siegelaar S, Heijboer A. Falsely decreased thyro globulin levels in a patient with differentiated thyroid carcinoma. Clinica Chimica Acta 2020;509:217-9.
Whitley RJ, Ain KB. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin Lab Med 2004;24:29-47.
Steurer S, Schneider J, Büscheck F, Luebke AM, Kluth M, Hube-Magg C, et al. Immunohistochemically detectable thyro globulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. Ann Diagn Pathol 2021;54:151793.
Baloch Z, Mete O, Asa SL. Immunohistochemical biomarkers in thyroid pathology. Endocr Pathol 2018;29:91-112.
Ryff-de Lèche A, Staub JJ, Kohler-Faden R, Müller-Brand JA, Heitz PU. Thyroglobulin production by malignant thyroid tumors. An immunocytochemical and radioimmunoassay study. Cancer 1986;57:1145-53.
Cameselle-Teijeiro JM, Eloy C, Sobrinho-Simões M. Pitfalls in challenging thyroid tumors: emphasis on differential diagnosis and ancillary biomarkers. Endocr Pathol 2020;31:197-217.
Nilsson JN, Siikanen J, Hedman C, Juhlin CC, Ihre Lundgren C. Pre-therapeutic measurements of Iodine avidity in papillary and poorly differentiated thyroid cancer reveal associations with thyroglobulin expression, histological variant and Ki-67 index. Cancers 2021;13:3627.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Prince of Songkla University, Thailand
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
